Patented technology allows for manufacturing hundreds of therapeutic doses of Killer T cells (Cytotoxic CD8+ T Lymphocytes) from a single donor Tevogen’s investigational T cell therapy, TVGN-489, is designed to detect targets spread across the entire viral genome rather than only spike proteins METUCHEN, N.J.–(BUSINESS WIRE)–#CD8—Tevogen Bio, a clinical stage biotechnology company specializing in cell […]

The post Tevogen Bio™ Further Strengthens IP Portfolio With Additional Patent for Method of Preparing Its Investigational SARS-CoV-2 Specific T cell Therapy appeared first on Fintech News.

As vaccinations continue to be rolled out globally, more countries are starting to open up their borders to tourists.